Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 26 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Hawkes N. German body calls for pause in European plan for fast track drug approval. BMJ 2016;354:i4479. [Ref.ID 100601]
3. Cita con resumen
Stafford N. German drug industry says pricing law is restricting access to some drugs. BMJ 2015;351:h6205. [Ref.ID 99692]
4.Tiene citas relacionadas Cita con resumen
Köhler M, Haag S, Biester K, Brockhaus AC, McGauran N, Grouven U, Kölsch H, Seay U, Hörn H, Moritz G, Staeck K, Wieseler B. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ 2015;350:h796. [Ref.ID 98850]
5.Tiene citas relacionadas Cita con resumen
Doshi P, Jefferson T. The evidence base for new drugs. BMJ 2015;350:h952. [Ref.ID 98849]
6.Tiene citas relacionadas Cita con resumen
Wieseler B, Wolfrm N, McGauran N, Kerekes MF, Vervölgyi V, Kohlepp P, Kamphuis M, Grouven U. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLOS Medicine 2013:15 de octubre. [Ref.ID 96365]
7.Tiene citas relacionadas Cita con resumen
Godlee F. Withdraw approval for Tamiflu until NICE has full data. BMJ 2012;345:27. [Ref.ID 94247]
8. Cita con resumen
Anónimo. H1 Reboxetine: benefit-risk balance reviewed. Drug Safety Update 2011;5:H1. [Ref.ID 90986]
9.Tiene citas relacionadas Cita con resumen
Krishnadas R. Reboxetine in depression. NICE guidance differs, so where next?. BMJ 2010;341:1064. [Ref.ID 89687]
10.Tiene citas relacionadas Cita con resumen
Turner EH. Reboxetine in depression. All the relevant data?. BMJ 2010;341:1064. [Ref.ID 89686]
11. Cita con resumen
Wieseler B, McGauran N, Kaiser T. Drug studies: a tale of hide and seek. BMJ 2010;341:809-10. [Ref.ID 89514]
12. Cita con resumen
Tuffs A. Experts criticise proposed new German law for favouring drug companies. BMJ 2010;341:798-9. [Ref.ID 89511]
13.Tiene citas relacionadas Cita con resumen
Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kraiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:816. [Ref.ID 89205]
14. Cita con resumen
Tuffs A. Head of German NICE was sacrificed to industry, says expert. BMJ 2010;340:499. [Ref.ID 88004]
15. Cita con resumen
Hyde R. Head of German cost-effectiveness institute forced to quit. Lancet 2010;375:540-1. [Ref.ID 87832]
16. Cita con resumen
Tuffs A. Doctors sign petition for head of German NICE to remain in post. BMJ 2010;340:177. [Ref.ID 87705]
17. Cita con resumen
Stafford N. German agency asks Pfizer to disclose all reboxetine data. BMJ 2009;338:1522. [Ref.ID 86141]
18.Tiene citas relacionadas Cita con resumen
Hawkes N. NICE goes global. BMJ 2009;338:266-7. [Ref.ID 85155]
19. Cita con resumen
Sawicki P, Bastian H. German health care: a bit of Bismarck plus more science. BMJ 2008;337:1142-5. [Ref.ID 84539]
20. Cita con resumen
Anónimo. Germany to stop reimbursing short-acting insulin for type 1 diabetes. Scrip 2008;3340:3. [Ref.ID 82303]
Seleccionar todas
 
 1 a 20 de 26 siguiente >>